Standard

Antithrombin plus alpha-1 protease inhibitor does not affect coagulation and inflammation in two murine models of acute lung injury. / Juschten, Jenny; Ingelse, Sarah Anne; Maas, Martinus Adrianus Wilhelmus; Girbes, Armand Roelof Johan; Juffermans, Nicole Petra; Schultz, Marcus Josephus; Tuinman, Pieter Roel.

In: Intensive Care Medicine Experimental, Vol. 7, No. Suppl 1, 36, 01.07.2019, p. 36.

Research output: Contribution to journalArticleAcademicpeer-review

Harvard

APA

Vancouver

Author

Juschten, Jenny ; Ingelse, Sarah Anne ; Maas, Martinus Adrianus Wilhelmus ; Girbes, Armand Roelof Johan ; Juffermans, Nicole Petra ; Schultz, Marcus Josephus ; Tuinman, Pieter Roel. / Antithrombin plus alpha-1 protease inhibitor does not affect coagulation and inflammation in two murine models of acute lung injury. In: Intensive Care Medicine Experimental. 2019 ; Vol. 7, No. Suppl 1. pp. 36.

BibTeX

@article{a8cae06087d548da8285b72393405537,
title = "Antithrombin plus alpha-1 protease inhibitor does not affect coagulation and inflammation in two murine models of acute lung injury",
abstract = "Background: In acute respiratory distress syndrome (ARDS), uncontrolled production of activators of coagulation and proinflammatory mediators results in a shift from an adequate local innate immune response to hypercoagulability and inflammation. This study aimed to investigate whether the protease inhibitors antithrombin (AT) and alpha-1 protease inhibitor (A1PI) may attenuate an exaggerated pulmonary immune response. Methods: Lung injury was induced either by single intranasal administration of lipopolysaccharide (LPS) (5 mg/kg) in BALB/c mice or by combination of an intravenous injection of LPS (10 mg/kg) with subsequent injurious ventilation using high tidal volumes (12–15 ml/kg) for 4 h in RccHan Wistar rats. Animals received either a single bolus of AT (250 IU/kg) or A1PI (60 mg/kg) alone or in combination, with or without intravenous low-dose heparin (100 U/kg). Control animals received saline. Additional controls received neither LPS, nor ventilation, nor treatment. Endpoints were local and systemic markers of coagulation, e.g., thrombin–antithrombin complexes (TATc), and inflammation, e.g., interleukin-6. Results: Both lung injury models resulted in a pronounced immune response within the pulmonary compartment shown by elevated levels of markers of coagulation and inflammation. The two-hit lung injury model also induced profound systemic coagulopathy and inflammation. Monotherapy with AT or A1PI did not reduce pulmonary coagulopathy or inflammation in any lung injury model. Nor did combination therapy with AT and A1PI result in a decrease of coagulation or inflammatory parameters. AT markedly reduced systemic levels of TATc in the two-hit lung injury model. Systemic inflammation was not affected by the different interventions. Additional administration of heparin did not lead to macroscopic bleeding incidences. Conclusions: In two different murine models of acute lung injury, neither single therapy with AT or A1PI nor combination of both agents attenuates the pronounced pulmonary coagulation or inflammatory response.",
keywords = "Acute lung injury, Alpha-1 protease inhibitor, Antithrombin, ARDS, Coagulation, Inflammation, Lung injury model",
author = "Jenny Juschten and Ingelse, {Sarah Anne} and Maas, {Martinus Adrianus Wilhelmus} and Girbes, {Armand Roelof Johan} and Juffermans, {Nicole Petra} and Schultz, {Marcus Josephus} and Tuinman, {Pieter Roel}",
note = "Publisher Copyright: {\textcopyright} 2019, The Author(s).",
year = "2019",
month = jul,
day = "1",
doi = "10.1186/s40635-019-0240-7",
language = "English",
volume = "7",
pages = "36",
journal = "Intensive Care Medicine Experimental",
issn = "2197-425X",
publisher = "Springer Science + Business Media",
number = "Suppl 1",

}

RIS

TY - JOUR

T1 - Antithrombin plus alpha-1 protease inhibitor does not affect coagulation and inflammation in two murine models of acute lung injury

AU - Juschten, Jenny

AU - Ingelse, Sarah Anne

AU - Maas, Martinus Adrianus Wilhelmus

AU - Girbes, Armand Roelof Johan

AU - Juffermans, Nicole Petra

AU - Schultz, Marcus Josephus

AU - Tuinman, Pieter Roel

N1 - Publisher Copyright: © 2019, The Author(s).

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Background: In acute respiratory distress syndrome (ARDS), uncontrolled production of activators of coagulation and proinflammatory mediators results in a shift from an adequate local innate immune response to hypercoagulability and inflammation. This study aimed to investigate whether the protease inhibitors antithrombin (AT) and alpha-1 protease inhibitor (A1PI) may attenuate an exaggerated pulmonary immune response. Methods: Lung injury was induced either by single intranasal administration of lipopolysaccharide (LPS) (5 mg/kg) in BALB/c mice or by combination of an intravenous injection of LPS (10 mg/kg) with subsequent injurious ventilation using high tidal volumes (12–15 ml/kg) for 4 h in RccHan Wistar rats. Animals received either a single bolus of AT (250 IU/kg) or A1PI (60 mg/kg) alone or in combination, with or without intravenous low-dose heparin (100 U/kg). Control animals received saline. Additional controls received neither LPS, nor ventilation, nor treatment. Endpoints were local and systemic markers of coagulation, e.g., thrombin–antithrombin complexes (TATc), and inflammation, e.g., interleukin-6. Results: Both lung injury models resulted in a pronounced immune response within the pulmonary compartment shown by elevated levels of markers of coagulation and inflammation. The two-hit lung injury model also induced profound systemic coagulopathy and inflammation. Monotherapy with AT or A1PI did not reduce pulmonary coagulopathy or inflammation in any lung injury model. Nor did combination therapy with AT and A1PI result in a decrease of coagulation or inflammatory parameters. AT markedly reduced systemic levels of TATc in the two-hit lung injury model. Systemic inflammation was not affected by the different interventions. Additional administration of heparin did not lead to macroscopic bleeding incidences. Conclusions: In two different murine models of acute lung injury, neither single therapy with AT or A1PI nor combination of both agents attenuates the pronounced pulmonary coagulation or inflammatory response.

AB - Background: In acute respiratory distress syndrome (ARDS), uncontrolled production of activators of coagulation and proinflammatory mediators results in a shift from an adequate local innate immune response to hypercoagulability and inflammation. This study aimed to investigate whether the protease inhibitors antithrombin (AT) and alpha-1 protease inhibitor (A1PI) may attenuate an exaggerated pulmonary immune response. Methods: Lung injury was induced either by single intranasal administration of lipopolysaccharide (LPS) (5 mg/kg) in BALB/c mice or by combination of an intravenous injection of LPS (10 mg/kg) with subsequent injurious ventilation using high tidal volumes (12–15 ml/kg) for 4 h in RccHan Wistar rats. Animals received either a single bolus of AT (250 IU/kg) or A1PI (60 mg/kg) alone or in combination, with or without intravenous low-dose heparin (100 U/kg). Control animals received saline. Additional controls received neither LPS, nor ventilation, nor treatment. Endpoints were local and systemic markers of coagulation, e.g., thrombin–antithrombin complexes (TATc), and inflammation, e.g., interleukin-6. Results: Both lung injury models resulted in a pronounced immune response within the pulmonary compartment shown by elevated levels of markers of coagulation and inflammation. The two-hit lung injury model also induced profound systemic coagulopathy and inflammation. Monotherapy with AT or A1PI did not reduce pulmonary coagulopathy or inflammation in any lung injury model. Nor did combination therapy with AT and A1PI result in a decrease of coagulation or inflammatory parameters. AT markedly reduced systemic levels of TATc in the two-hit lung injury model. Systemic inflammation was not affected by the different interventions. Additional administration of heparin did not lead to macroscopic bleeding incidences. Conclusions: In two different murine models of acute lung injury, neither single therapy with AT or A1PI nor combination of both agents attenuates the pronounced pulmonary coagulation or inflammatory response.

KW - Acute lung injury

KW - Alpha-1 protease inhibitor

KW - Antithrombin

KW - ARDS

KW - Coagulation

KW - Inflammation

KW - Lung injury model

UR - http://www.scopus.com/inward/record.url?scp=85072866266&partnerID=8YFLogxK

U2 - 10.1186/s40635-019-0240-7

DO - 10.1186/s40635-019-0240-7

M3 - Article

C2 - 31346884

VL - 7

SP - 36

JO - Intensive Care Medicine Experimental

JF - Intensive Care Medicine Experimental

SN - 2197-425X

IS - Suppl 1

M1 - 36

ER -

ID: 10587291